home About Us People Portfolio News Contact Us Fund II Investor Login » Fund III Investor Login » Fund IV Investor Login »

TriVascular

$96 million

Medical Device
Cardiovascular

Oct26
2014
Endologix, Inc. and TriVascular Technologies, Inc. Announce Merger to Create a Leading Cardiovascular Growth Company Focused on the Treatment of Aortic Disorders »

Aug4
2014
TriVascular Technologies, Inc. Receives FDA Approval of the Ovation iX(TM) Abdominal Stent Graft System »

Aug4
2014
Trivascular Technologies, Inc. and CRG Modify Term Loan Agreement »

Jun15
2014
TriVascular Technologies, Inc. Announces FDA Approval of Ovation iX(TM) Iliac Stent Graft »

Nov10
2014
TriVascular Technologies, Inc. and CRG LP Amend and Restate Term Loan Facility »

Oct15
2014
TriVascular Announces FDA Approval of CustomSeal(TM) Technology for the Ovation Prime(R) System »

Apr29
2014
TriVascular Announces FDA-Approved Expansion of Ovation® and Ovation Prime™ Indication Statements »

Apr22
2014
TriVascular Technologies, Inc. Announces the Closing of Its Initial Public Offering »

Santa Rosa, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- TriVascular Technologies, Inc. (Nasdaq:TRIV), manufacturer of the Ovation Prime™ Abdominal Stent Graft System, today announced the closing of its initial public offering of 7,475,000 shares of its common stock at a public offering price of $12.00 per share, including 975,000 shares sold pursuant to the underwriter's option to purchase additional shares. The company's shares began trading on The NASDAQ Global Select Market on April 16, 2014 under the ticker symbol "TRIV."

 

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. Canaccord Genuity Inc. and Stifel, Nicolaus & Company, Incorporated acted as co-managers.

 

A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on April 15, 2014. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by telephone at (800) 221-1037 or by email at newyork.prospectus@credit-suisse.com.

 

About TriVascular Technologies, Inc.

 

TriVascular is a medical device company developing and commercializing innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. The company manufactures the Ovation Prime Abdominal Stent Graft System, the lowest profile FDA-approved system, which utilizes a novel, polymer-based sealing mechanism. TriVascular is based in Santa Rosa, California.

 

CONTACT:

 

Investor Relations Contact:

 

Michael Kramer

Chief Financial Officer

+1-707.543.8709

Apr15
2014
TriVascular Technologies, Inc. Announces Pricing of Initial Public Offering »

Nov18
2014
TriVascular Secures $40 Million in Equity Financing »

Feb5
2014
TriVascular and Capital Royalty Close Term Loan Facility »

Jan21
2014
TriVascular Receives U.S. FDA Approval for the Ovation Prime™ Abdominal Stent Graft System »